高级搜索

食管癌术后复发患者调强放疗同步化疗(5-Fu+奈达铂)的Ⅱ期临床研究

陶华, 孔诚, 陆进成

陶华, 孔诚, 陆进成. 食管癌术后复发患者调强放疗同步化疗(5-Fu+奈达铂)的Ⅱ期临床研究[J]. 肿瘤防治研究, 2012, 39(10): 1261-1264. DOI: 10.3971/j.issn.1000-8578.2012.10.026
引用本文: 陶华, 孔诚, 陆进成. 食管癌术后复发患者调强放疗同步化疗(5-Fu+奈达铂)的Ⅱ期临床研究[J]. 肿瘤防治研究, 2012, 39(10): 1261-1264. DOI: 10.3971/j.issn.1000-8578.2012.10.026
Tao Hua, Kong Cheng, Lu Jincheng. Phase Ⅱ Study of Intensity-Modulated Radiotherapy Combined with 5-Fluorouracil and Nedaplatin Chemotherapy in Recurrent Esophageal Carcinoma after Curative Operation[J]. Cancer Research on Prevention and Treatment, 2012, 39(10): 1261-1264. DOI: 10.3971/j.issn.1000-8578.2012.10.026
Citation: Tao Hua, Kong Cheng, Lu Jincheng. Phase Ⅱ Study of Intensity-Modulated Radiotherapy Combined with 5-Fluorouracil and Nedaplatin Chemotherapy in Recurrent Esophageal Carcinoma after Curative Operation[J]. Cancer Research on Prevention and Treatment, 2012, 39(10): 1261-1264. DOI: 10.3971/j.issn.1000-8578.2012.10.026

食管癌术后复发患者调强放疗同步化疗(5-Fu+奈达铂)的Ⅱ期临床研究

基金项目: 江苏省肿瘤医院中青年基金资助项目(ZQ200903)
详细信息
    作者简介:

    陶华(1977-),女,硕士,主治医师,主要从事肿瘤的放射治疗工作

    通讯作者:

    陆进成,E-mail:lujincheng@msn.com

  • 中图分类号: R735.1

Phase Ⅱ Study of Intensity-Modulated Radiotherapy Combined with 5-Fluorouracil and Nedaplatin Chemotherapy in Recurrent Esophageal Carcinoma after Curative Operation

  • 摘要: 目的 评价食管癌根治术后复发患者调强放疗同步化疗(5-Fu+奈达铂)的近期疗效和不良反应。方法选取2009年6月—2010年6月44例符合入组条件的食管癌术后复发患者,均采用调强放疗同步化疗(5-Fu+奈达铂)方案进行治疗。调强放疗:GTV给量60 Gy/30 f,2.0 Gy/f;CTV给量54 Gy/30 f,1.8 Gy/f。同步化疗在放疗的第1周和第4周进行,具体为:5-Fu 750 mg/(m2·d),d1~5,奈达铂80 mg/(m2·d),d1。主要观察终点是1年生存率,次要观察终点是不良反应。结果全组总有效率为86%(38/44)。1年和2年总生存率分别为72.7%和60%。1年和2年无进展生存率分别为63.6%和36.6%。放化疗期间出现Ⅰ、Ⅱ和Ⅲ度骨髓抑制的患者分别为16%(7/44)、50%(22/44)和34%(15/44);出现Ⅰ度和Ⅱ度胃肠道反应的患者分别为45%(20/44)、55%(24/44);出现Ⅰ度和Ⅱ度肝/肾功能生化指标异常的患者分别为77%(34/44)、23%(10/44),未发现Ⅲ度及以上胃肠道及肝/肾功能生化指标异常者。所有不良反应经对症处理后均好转,全组患者均顺利完成放化疗计划,无疗程中断或延迟者。结论食管癌根治术后复发患者进行调强放疗同步化疗(5-Fu+奈达铂)的近期疗效好,不良反应小,值得进行Ⅲ期临床研究。

     

    Abstract: Objective To analyze the feasibility and safety of postoperative recurrent esophageal carcinoma patients treated by intensity-modulated radiotherapy combined with 5-Fluorouracil(5-Fu) and nedaplatin chemotherapy. Methods Forty-four esophageal carcinoma patients suffered recurrence after their definitive resection in our department from June 2009 to June 2010.Intensity-modulated radiotherapy combined with 5-Fu and nedaplatin chemotherapy was performed in the patients(gross tumor volume,GTV) of IMRT was prescribed to 60 Gy/30f,2.0 Gy/f and 5-Fu and nedaplatin concurrent chemotherapy was used by 5-Fu 750 mg/(m2·d),d1~5,nedaplatin 80 mg/(m2·d),d1 at week 1 and week 4.The primary endpoint was 1-year survival rate and the second endpoint was toxicity related to the treatment. Results The overall response rate (CR+PR) was 86%(38/44).1- and 2-year overall survival rate was 72.7% and 60%,respectively.1- and 2-year progression-free survival rate was 63.6% and 36.6%,respectively.Univariate analysis outcome showed that only recurrent site was related with prognosis (χ2=22.848,P=0.000).All the patients undergone this treatment smoothly.Grade Ⅰ,Ⅱ and Ⅲ leukocytopenia was observed in 16% (7/44),50% (22/44),and 34% (15/44) patients,respectively.Grade I,and II digestive tract toxicity was observed in 45% (20/44),55% (24/44) patients,respectively.Grade Ⅰ,and Ⅱ liver/renal toxicity was observed in 77% (34/44),and 23% (10/44) patients,respectively.Over grade 3 digestive tract and liver/renal toxicity were not found.All the toxicities were gone after corresponding therapy. Conclusion Concurrent chemotherapy with 5-Fu and nedaplatin plus intensity-modulated radiotherapy is an effective and feasible regimen and would be considered as a better option for postoperative recurrent esophageal carcinoma patients,which could be deserved to be applied to phase Ⅲ clinical trial.

     

  • [1] Jemal A,Bray F,Center MM,et al.Global Cancer Statistics [J].CA Cancer J Clin,2011,61(2):69-90.
    [2] Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009[J].CA Cancer J Clin,2009,59(4):225-49.
    [3] Enzinger PC,Mayer RJ.Esophageal cancer [J].N Engl J Med,2003,349(23):2241-52.
    [4] Abate E,DeMeester SR,Zehetner J,et al.Recurrence after esophagectomy for adenocarcinoma:defining optimalfollow-up intervals and testing[J].J Am Coll Surg,2010,210(4):428-35.
    [5] Kunisaki C,Makino H,Takagawa R,et al.Surgical outcomes in esophageal cancer patients with tumor recurrenceafter curative esophagectomy [J].J Gastrointest Surg,2008,12(5):802-10.
    [6] Wang YX,Zhu SC,Li R,et al.Radiotherapy for postoperative regional recurrence in esophageal carcinoma[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2005,14(2):86-9.[王玉祥,祝淑钗,李任,等.食管癌术后区域性复发的放疗[J].中华放射肿瘤学杂志,2005,14(2):86-9.]
    [7] Zhang JR,Yang J,Lv Y,et al.Effect of radiotherapy on loco-regional recurrence of esophageal carcinoma aftersurgery[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2010,19(4) :302-5.[张瑾熔,杨蛟,吕茵,等.91例术后局部复发转移食管癌放疗疗效和预后分析[J].中华放射肿瘤学杂志,2010,19(4) :302-5.]
    [8] Jin J,Wang LH,Yin WB,et al.Radiotherap for postoperative anastomosis recurrence in esophageal carcinoma[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2000,9(2):87-9.[金晶,王绿化,殷蔚伯,等.食管癌根治术后吻合口复发的放疗[J].中华放射肿瘤学杂志,2000,9(2):87-9.]
    [9] Lu JC,Kong C,Tao H.Radiotherapy with or without concurrent chemotherapy for lymph node recurrence afterradical surgery of thoracic esophageal squamous cell carcinoma[J].Int J Radiat Oncol Biol Phys,2010,78(3):710-4.
    [10] Carlisle JG,Quint LE,Francis IR,et al.Recurrent esophageal carcinoma:CT evaluation after esophagectomy [J].Radiology,1993,189(1):271-5.
    [11] Nemoto K,Ariga H,Kakuto Y,et al.Radiation therapy for loco-regionally recurrent esophageal cancer aftersurgery [J].Radiother Oncol,2001,61(2):165-8.
    [12] Raoul JL,Le Prisé E,Meunier B,et al.Combined radiochemotherapy for postoperative recurrence of oesophagealcancer[J].Gut,1995,37(2):174-6.
    [13] Nishimura Y,Koike R,Nakamatsu K,et al.Concurrent chemoradiotherapy with protracted infusion of 5-Fu andCisplatin for postoperative recurrent or residual esophageal cancer[J].Jpn J Clin Oncol,2003,33(7):341-5.
    [14] Uchida N,Takeda Y,Hojo K,et al.Sequence-dependent antitumour efficacy of combination chemotherapy ofnedaplatin,a novel platinum complex,with 5-fluorouracil in an in vivo murine tumour model[J].Eur JCancer,1998,34(11):1796-801.
    [15] Nemoto K,Matsushita H,Ogawa Y,et al.Radiation therapy combined with cis-diammine-glycolatoplatinum(Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer[J].Am J Clin Oncol,2003,26(1):46-9.
    [16] Jingu K,Nemoto K,Matsushita H,et al.Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum and 5-Fluorouracil for postoperative locoregional recurrent esophageal cancer[J].BMCCancer,2006,6:50.
计量
  • 文章访问数:  2322
  • HTML全文浏览量:  18
  • PDF下载量:  663
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-11-15
  • 修回日期:  2012-03-27
  • 刊出日期:  2012-10-24

目录

    /

    返回文章
    返回